The global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety concerns remain significant challenges.

The CRISPR-based drug development platforms market is projected to grow at a CAGR of 11.4%, reaching USD 0.79 billion by 2031 from USD 0.46 billion in 2026. Growth is driven by advancements in precision medicine, gene therapy expansion, and increased biotech investments, though regulatory challenges and high development costs remain constraints.

Intellia Therapeutics, a CRISPR gene-editing biotech company, has surged 70% this year and Wall Street expects another 70% gain over the next 12 months. The company is preparing FDA submission for lonvo-z, a one-time treatment for hereditary angioedema that showed 87% reduction in attacks in phase 3 trials. With positive clinical data and a second late-stage candidate in development, Intellia is transitioning toward commercial-stage operations.

The article compares two emerging biotech stocks: Intellia Therapeutics, which focuses on CRISPR gene-editing technology with promising Phase III trial data but significant losses and clinical risks, and Omeros, which recently achieved FDA approval for Yartemlea and posted its first commercial revenue of $9.89 million. While Intellia offers higher upside potential, Omeros is deemed the safer choice due to its transition to profitability, strong initial sales, and healthier balance sheet, despite trading at a premium valuation.

Intellia Therapeutics' stock has surged 58% year-to-date following positive phase 3 trial results for lonvo-z, a gene-editing treatment for hereditary angioedema. While lonvo-z shows promise with an 87% reduction in attacks, its commercial opportunity is limited to a small patient population (~7,000 in the U.S.), potentially generating $3.5 billion in lifetime sales. The company's more promising pipeline candidate, nex-z for transthyretin amyloidosis, won't show results until 2027. Investors should weigh significant clinical and regulatory risks against potential upside.

Intellia Therapeutics announced positive Phase 3 HAELO trial results for lonvo-z, a CRISPR gene-editing treatment for hereditary angioedema (HAE). The treatment achieved an 87% reduction in monthly attacks versus placebo, with 62% of patients attack-free during the evaluation period. The company initiated a rolling BLA submission with the FDA and expects U.S. approval and launch in the first half of 2027.

Warren Buffett and Greg Abel's Berkshire Hathaway portfolio is notably absent from the healthcare sector, holding only DaVita and recently exiting UnitedHealth Group. The article argues investors should consider healthcare independently, as it offers opportunities across multiple investment styles—from high-growth pharma/biotech plays like Eli Lilly to dividend-paying stalwarts like Johnson & Johnson and Abbott Laboratories that provide steady earnings and income.

Cathie Wood's Ark Invest added to positions in Shopify, Intellia Therapeutics, and GeneDX on Tuesday as all three stocks experienced significant declines. Shopify fell 16% after disappointing guidance despite strong quarterly results. GeneDX plummeted 49% following weak earnings and a major downward revision of full-year revenue guidance. Intellia Therapeutics had a modest 4% decline and remains supported by positive clinical trial data.

Intellia Therapeutics priced an underwritten public offering of 16.7 million shares at $10.75 per share, generating approximately $180 million in gross proceeds. The offering is being managed by Jefferies, Goldman Sachs, and Citigroup. The company is a clinical-stage biopharmaceutical firm focused on CRISPR gene editing technologies.

U.S. equity markets held near record highs despite geopolitical tensions in the Middle East driving oil prices above $100/barrel. The collapse of U.S.-Iran negotiations triggered an energy shock, while major tech developments included OpenAI's partnership with Qualcomm on smartphone processors, Microsoft's loss of exclusive OpenAI access, and China's forced unwinding of Meta's AI acquisition. Consumer weakness emerged with Domino's cutting guidance, while positive credit metrics in auto lending and a gene-editing breakthrough in CRISPR therapy provided bright spots.

With a $300 billion patent cliff expected by 2030, biotech M&A activity is surging. The article identifies three gene-editing companies positioned as potential acquisition targets: CRISPR Therapeutics (established with commercial product), Intellia Therapeutics (pioneering in vivo CRISPR editing), and Beam Therapeutics (developing base editing technology). Each offers different risk/reward profiles for investors seeking exposure to one-time cure therapies.

Intellia Therapeutics awarded inducement grants to 13 new employees on April 1, 2026, consisting of 67,150 restricted stock units vesting over three years under the company's 2024 Inducement Plan. The grants were approved by the compensation committee as a material inducement to employment in accordance with Nasdaq regulations.